Top Page
Pro Medicus Limited
(Sydney:PME)
Pro Medicus Limited (PME) vs. iShares MSCI Australia ETF (EWA)
Pro Medicus Limited Business Overview & Revenue Model
Pro Medicus Limited Earnings Call Summary
Pro Medicus Limited Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 240.57M | 212.91M | 161.43M | 124.90M | 93.46M | 67.88M |
| Gross Profit | 188.62M | 212.60M | 122.24M | 92.36M | 92.94M | 46.66M |
| EBITDA | 188.50M | 164.85M | 120.69M | 91.69M | 69.64M | 49.53M |
| Net Income | 234.69M | 115.22M | 82.79M | 60.65M | 44.44M | 30.85M |
Balance Sheet | ||||||
| Total Assets | 533.91M | 338.70M | 257.43M | 202.13M | 157.05M | 125.57M |
| Cash, Cash Equivalents and Short-Term Investments | 223.59M | 209.19M | 154.89M | 121.50M | 90.55M | 61.82M |
| Total Debt | 4.32M | 2.25M | 2.07M | 1.85M | 2.28M | 2.62M |
| Total Liabilities | 144.99M | 81.74M | 69.70M | 63.36M | 55.32M | 43.89M |
| Stockholders Equity | 388.93M | 256.96M | 187.73M | 138.78M | 101.73M | 81.68M |
Cash Flow | ||||||
| Free Cash Flow | 135.53M | 103.95M | 80.08M | 58.33M | 53.20M | 31.33M |
| Operating Cash Flow | 136.00M | 111.33M | 86.78M | 64.77M | 62.23M | 39.02M |
| Investing Cash Flow | -23.89M | -6.58M | -78.07M | -9.79M | -17.56M | -27.40M |
| Financing Cash Flow | -76.22M | -57.62M | -39.84M | -27.53M | -23.31M | -14.05M |
Pro Medicus Limited Technical Analysis
Pro Medicus Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $11.94B | 33.69 | 50.70% | 0.24% | 31.88% | 39.10% | |
67 Neutral | AU$131.61M | 26.51 | 1.89% | ― | 10.06% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$76.38M | -6.28 | -12.35% | ― | 15.99% | 22.05% | |
47 Neutral | AU$18.13M | 3.95 | -17.05% | ― | 28.91% | -1050.00% | |
45 Neutral | AU$35.53M | -3.13 | -8647.54% | ― | 25.98% | 22.10% |
Pro Medicus Limited Corporate Events
Pro Medicus director Anthony Barry Hall has increased his direct holding in the company through an on-market purchase of 8,146 ordinary shares at $122.00 per share. Following the transaction, Hall’s total interest rose to 24,174,166 shares, spread across his personal holding, the Akay Superannuation Fund, the Anthony Hall Family Trust, and the Anthony Hall Testamentary Trust.
The move modestly lifts insider ownership in Pro Medicus, underscoring Hall’s continued financial commitment to the company. The acquisition may be viewed by investors as a vote of confidence in the company’s prospects, although no changes were reported in any related contracts or derivative interests.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$128.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus director Anthony Barry Hall has increased his direct interest in the company through an on-market purchase of additional ordinary shares. The transaction reflects a modest increase in his overall holding structure across personal, superannuation, family trust, and testamentary trust entities.
Hall acquired 9,000 ordinary shares at a price of $114.41 per share, taking his total relevant interest from 24,157,020 to 24,166,020 shares. The change does not involve any disposals or contractual interest changes, indicating a straightforward on-market expansion of his equity stake in Pro Medicus.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$128.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus director Anthony Barry Hall has increased his direct shareholding in the company through an on-market trade. Hall acquired 8,500 ordinary shares at $110.13 per share via Research Corporation Pty Ltd as trustee for the Anthony Hall Family Trust.
Following the purchase, Hall’s total relevant interest in Pro Medicus has risen from 24,148,520 to 24,157,020 ordinary shares across several entities. The incremental increase underlines ongoing insider alignment with shareholders, though it does not materially alter the company’s overall capital structure.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$128.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has disclosed a change in the shareholding of director Sam Aaron Hupert, who increased his direct interest in the company through an on‑market purchase. Hupert acquired 4,500 ordinary shares at $108.72 per share via ALLHC Pty Ltd as trustee for the Sam Hupert Family Trust.
Following the transaction, Hupert’s total holding rose to 24,196,660 ordinary shares across his personal name, the Alltogether Superannuation Fund, and the family trust. The incremental purchase signals continued alignment of the director’s financial interests with those of other shareholders, although the percentage impact on overall capital is modest.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$128.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has reported a small increase in the shareholding of director Peter Terence Kempen, reflecting a further on-market investment in the company. Kempen holds his interest directly and through related entities, including a superannuation fund and EMK Investments Pty Ltd, where he is a director and beneficial owner.
The filing shows Kempen acquired 400 additional ordinary shares on 23 February 2026 at $116.43 per share, lifting his total holding to 630,082 shares. The transaction, executed as an on-market purchase, signals continued alignment of the director’s financial interests with those of other shareholders, though it represents only a modest incremental change in overall ownership.
The most recent analyst rating on (AU:PME) stock is a Hold with a A$137.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has announced that it will release its half-year 2026 financial results on Thursday, 12 February 2026, underscoring an upcoming milestone for investors and analysts tracking the health imaging specialist’s performance. The company will accompany the release with a webcast conference call on the same day at 11:00am AEDT, offering stakeholders an opportunity to hear management commentary and gain further insight into operational trends and the company’s positioning in the medical imaging technology market.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$225.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has notified the market of the issue of 47,930 unquoted performance rights under its employee incentive scheme, effective 3 September 2021. The move underscores the company’s continued use of equity-based remuneration to align staff and management interests with shareholders, potentially supporting employee retention and long-term value creation without immediately increasing the free float of tradable shares.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has notified the market that 3,134 performance rights (PMEAL) have lapsed after the conditions attached to these rights were not met or became incapable of being satisfied, effective 31 October 2025. The cessation of these securities represents a minor adjustment to the company’s issued capital structure and reflects the operation of its performance-based incentive arrangements, with limited immediate impact on ordinary shareholders but some implications for the allocation of executive or employee equity incentives.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has notified the market of the planned issue of 27,986 unquoted performance rights under its employee incentive scheme, scheduled for 3 September 2025. The move underscores the company’s ongoing use of equity-based remuneration to attract and retain key staff, aligning employee incentives with long‑term shareholder value without diluting the quoted share base in the near term.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has notified the market of the issue of 40,358 unquoted performance rights under its employee incentive scheme, with an issue date of 28 August 2024. The move underscores the company’s ongoing use of equity-based remuneration to align staff incentives with long-term shareholder value, while not affecting the free float as the securities are not intended to be quoted on the ASX.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has cancelled 40,876 ordinary fully paid shares following an on‑market buy-back completed on 19 December 2025. The reduction in issued capital marginally enhances earnings per share and reflects ongoing capital management, signalling continued confidence from the company in its financial position and long-term outlook for shareholders.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has disclosed a small on-market share purchase by non-executive director Peter Terence Kempen, who increased his direct and associated holdings by 600 ordinary shares at a price of $224 per share. Following the transaction, Kempen’s total interest in the company rose to 629,682 shares held across his own name, the Elaine Kempen Superannuation Fund, and EMK Investments Pty Ltd, signalling continued insider confidence and marginally strengthening director alignment with shareholders.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has disclosed a small increase in the shareholding of director Anthony Barry Hall, who acquired 2,270 additional ordinary shares in an on-market trade at $220.31 per share. Following the transaction, Hall’s total relevant interest in Pro Medicus has risen to 24,148,520 ordinary shares held across various personal, superannuation and family trust structures, underscoring continued insider confidence and maintaining his significant stake in the company.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has disclosed a minor change in the shareholding of Director Sam Aaron Hupert, who has increased his direct interest in the company through an on‑market purchase of 2,250 ordinary shares at $221.99 per share. The transaction, executed via ALLHC Pty Ltd as trustee for the Sam Hupert Family Trust, lifts Hupert’s total holding to 24,192,160 ordinary shares, slightly reinforcing the director’s equity stake and signalling continued alignment of management interests with those of shareholders.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus director Anthony Barry Hall has marginally increased his stake in the healthcare imaging software group through an on-market purchase of additional ordinary shares. Hall acquired 2,250 Pro Medicus shares on 22 December 2025 at $221.90 per share via Research Corporation Pty Ltd as trustee for the Anthony Hall Family Trust, lifting his total holding to 24,146,250 shares across various entities, a move that signals ongoing confidence in the company but does not materially alter its capital structure.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has disclosed a change in the holdings of director Sam Aaron Hupert, who has increased his direct interest in the company through an on-market purchase of 2,250 ordinary shares at $221.45 per share via ALLHC Pty Ltd as trustee for the Sam Hupert Family Trust. Following the transaction, Hupert’s total holding has risen marginally to 24,189,910 ordinary shares across his personal, superannuation and family trust structures, signalling ongoing alignment of the director’s financial interests with those of shareholders but without materially altering the company’s ownership structure.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has provided an updated notification to the ASX regarding its on-market share buy-back of ordinary fully paid shares under code PME. The company reported that it had repurchased a total of 45,324 shares prior to the previous trading day and a further 3,200 shares on the previous day, as part of an ongoing buy-back program first notified in April 2025, with this update dated 19 December 2025, indicating continued capital management activity that may support earnings per share and signal confidence in the company’s valuation to investors.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has announced an update regarding its ongoing on-market buy-back program, with a recent purchase of 2,100 ordinary fully paid securities, bringing the total bought back to 43,224. This buy-back initiative reflects the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has announced an update on its ongoing share buy-back program, with a total of 1,060 ordinary fully paid securities bought back on the previous day, adding to the 42,164 securities bought back prior. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially increase shareholder value, reflecting a proactive approach to managing its financial resources.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has announced an update regarding its ongoing on-market buy-back program, which involves the repurchase of its ordinary fully paid shares. As of December 12, 2025, the company has bought back a total of 42,164 shares, including 1,025 shares acquired on the previous day. This buy-back initiative is part of the company’s strategy to optimize its capital structure and enhance shareholder value.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has announced an update on its ongoing on-market buy-back program, with a total of 39,001 securities bought back before the previous day and an additional 2,138 securities acquired on the previous day. This buy-back initiative reflects the company’s strategy to optimize its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has announced an update regarding its ongoing buy-back program, with a total of 4,000 ordinary fully paid securities bought back on the previous day, adding to a cumulative total of 35,001 securities repurchased. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value, reflecting a proactive approach to managing its financial resources.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has addressed recent speculation regarding a data breach involving Visage Imaging. The company confirmed that an unauthorized access incident occurred in July 2025, affecting a single email inbox, but no client systems or patient data were compromised. The breach was contained, and external cybersecurity experts were engaged. While some personal information of approximately 100 employees might have been accessed, no financial loss or operational impact was reported. Pro Medicus has informed affected individuals and relevant authorities, ensuring compliance with legal obligations.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.